Found: 69
Select item for more details and to access through your institution.
An evaluation of therapeutic synergism using linear logit models.
- Published in:
- Journal of Applied Statistics, 1989, v. 16, n. 3, p. 321, doi. 10.1080/02664768900000040
- By:
- Publication type:
- Article
Some simple log-linear models for the analysis of ordinal response data.
- Published in:
- Journal of Applied Statistics, 1988, v. 15, n. 3, p. 285, doi. 10.1080/02664768800000039
- By:
- Publication type:
- Article
Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, n. 5, p. 800, doi. 10.1093/cid/civ495
- By:
- Publication type:
- Article
Changes are still needed on multiple co-primary endpoints.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Two approaches for the analysis of a titration study with a placebo control.
- Published in:
- Communications in Statistics: Theory & Methods, 1988, v. 17, n. 3, p. 821, doi. 10.1080/03610928808829657
- By:
- Publication type:
- Article
Challenge of multiple co-primary endpoints: a new approach.
- Published in:
- Statistics in Medicine, 2007, v. 26, n. 6, p. 1181, doi. 10.1002/sim.2604
- By:
- Publication type:
- Article
Discussion.
- Published in:
- Statistics in Medicine, 2006, v. 25, n. 19, p. 3297, doi. 10.1002/sim.2643
- By:
- Publication type:
- Article
Tutorial in Biostatistics A review of tests for detecting a monotone dose-response relationship with ordinal response data.
- Published in:
- Statistics in Medicine, 1997, v. 16, n. 22, p. 2599, doi. 10.1002/(SICI)1097-0258(19971130)16:22<2599::AID-SIM734>3.0.CO;2-9
- By:
- Publication type:
- Article
Implementation of AMNOG: An industry perspective.
- Published in:
- Biometrical Journal, 2016, v. 58, n. 1, p. 76, doi. 10.1002/bimj.201300256
- By:
- Publication type:
- Article
A Cautionary Note on Design Implications when the Primary Analysis is a Stratified Analysis of a Binary Endpoint.
- Published in:
- Biometrical Journal, 2006, v. 48, n. 6, p. 978, doi. 10.1002/bimj.200610291
- By:
- Publication type:
- Article
The Acute Stroke Therapy by Inhibition of Neutrophils study – Key features and impact.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 4, p. 720, doi. 10.1002/pst.2218
- By:
- Publication type:
- Article
Lessons from meta‐analyses of randomized clinical trials for analysis of distributed networks of observational databases.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 1, p. 65, doi. 10.1002/pst.1908
- By:
- Publication type:
- Article
A comparison of five approaches to decision-making for a first clinical trial of efficacy.
- Published in:
- Pharmaceutical Statistics, 2017, v. 16, n. 1, p. 37, doi. 10.1002/pst.1775
- By:
- Publication type:
- Article
The shrinking or disappearing observed treatment effect.
- Published in:
- Pharmaceutical Statistics, 2014, v. 13, n. 5, p. 277, doi. 10.1002/pst.1633
- By:
- Publication type:
- Article
Subgroup analyses in cost-effectiveness analyses to support health technology assessments.
- Published in:
- Pharmaceutical Statistics, 2014, v. 13, n. 4, p. 265, doi. 10.1002/pst.1626
- By:
- Publication type:
- Article
Strong control over multiple endpoints: are we adding value to the assessment of medicines?
- Published in:
- Pharmaceutical Statistics, 2013, v. 12, n. 4, p. 189, doi. 10.1002/pst.1574
- By:
- Publication type:
- Article
Subgroup analyses of clinical effectiveness to support health technology assessments.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 6, p. 532, doi. 10.1002/pst.531
- By:
- Publication type:
- Article
The role of the minimum clinically important difference and its impact on designing a trial.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 250, doi. 10.1002/pst.459
- By:
- Publication type:
- Article
Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 3, doi. 10.1002/pst.397
- By:
- Publication type:
- Article
What should be the role of homogeneity testing in adaptive trials?
- Published in:
- Pharmaceutical Statistics, 2009, v. 8, n. 1, p. 1, doi. 10.1002/pst.342
- By:
- Publication type:
- Article
A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressant.
- Published in:
- Pharmaceutical Statistics, 2007, v. 6, n. 1, p. 9, doi. 10.1002/pst.234
- By:
- Publication type:
- Article
Sample size and the probability of a successful trial.
- Published in:
- Pharmaceutical Statistics, 2006, v. 5, n. 4, p. 305, doi. 10.1002/pst.232
- By:
- Publication type:
- Article
Editorial.
- Published in:
- Pharmaceutical Statistics, 2005, v. 4, n. 4, p. 231, doi. 10.1002/pst.196
- By:
- Publication type:
- Article
Four case studies to highlight some opportunities and challenges in developing anti-bacterial and anti-fungal agents.
- Published in:
- Pharmaceutical Statistics, 2005, v. 4, n. 4, p. 253, doi. 10.1002/pst.184
- By:
- Publication type:
- Article
Editorial.
- Published in:
- Pharmaceutical Statistics, 2004, v. 3, n. 3, p. 155, doi. 10.1002/pst.134
- By:
- Publication type:
- Article
Editorial.
- Published in:
- Pharmaceutical Statistics, 2005, v. 4, n. 3, p. 153, doi. 10.1002/pst.187
- By:
- Publication type:
- Article
Editorial.
- Published in:
- Pharmaceutical Statistics, 2005, v. 4, n. 2, p. 85, doi. 10.1002/pst.171
- By:
- Publication type:
- Article
Seize the opportunities.
- Published in:
- Pharmaceutical Statistics, 2004, v. 3, n. 3, p. 157, doi. 10.1002/pst.133
- By:
- Publication type:
- Article
Editorial.
- Published in:
- Pharmaceutical Statistics, 2005, v. 4, n. 1, p. 1, doi. 10.1002/pst.163
- By:
- Publication type:
- Article
Editorial.
- Published in:
- Pharmaceutical Statistics, 2004, v. 3, n. 4, p. 235, doi. 10.1002/pst.150
- By:
- Publication type:
- Article
Editorial.
- Published in:
- Pharmaceutical Statistics, 2004, v. 3, n. 2, p. 75, doi. 10.1002/pst.122
- By:
- Publication type:
- Article
Editorial.
- Published in:
- Pharmaceutical Statistics, 2004, v. 3, n. 1, p. 1, doi. 10.1002/pst.102
- By:
- Publication type:
- Article
Type I error and power in trials with one interim futility analysis.
- Published in:
- Pharmaceutical Statistics, 2004, v. 3, n. 1, p. 51, doi. 10.1002/pst.93
- By:
- Publication type:
- Article
Editorial.
- Published in:
- Pharmaceutical Statistics, 2003, v. 2, n. 4, p. 237, doi. 10.1002/pst.94
- By:
- Publication type:
- Article
Editorial.
- Published in:
- Pharmaceutical Statistics, 2003, v. 2, n. 3, p. 159, doi. 10.1002/pst.79
- By:
- Publication type:
- Article
Editorial.
- Published in:
- Pharmaceutical Statistics, 2003, v. 2, n. 1, p. 1, doi. 10.1002/pst.46
- By:
- Publication type:
- Article
Editorial.
- Published in:
- Pharmaceutical Statistics, 2002, v. 1, n. 1, p. 3, doi. 10.1002/pst.1
- By:
- Publication type:
- Article
Adaptivity in drug discovery and development.
- Published in:
- Drug Development Research, 2009, v. 70, n. 3, p. 169, doi. 10.1002/ddr.20285
- By:
- Publication type:
- Article
Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job.
- Published in:
- 2020
- By:
- Publication type:
- journal article
p-Values and Replicability: A Commentary on "The Role of p-Values in Judging the Strength of Evidence and Realistic Replication Expectations".
- Published in:
- Statistics in Biopharmaceutical Research, 2021, v. 13, n. 1, p. 36, doi. 10.1080/19466315.2020.1807404
- By:
- Publication type:
- Article
Statistical Considerations for Cardiovascular Outcome Trials in Patients with Type 2 Diabetes Mellitus.
- Published in:
- Statistics in Biopharmaceutical Research, 2017, v. 9, n. 4, p. 347, doi. 10.1080/19466315.2017.1280411
- By:
- Publication type:
- Article
Integrated Data Analysis for Assessing Treatment Effect through Combining Information from All Sources.
- Published in:
- Statistics in Biopharmaceutical Research, 2017, v. 9, n. 1, p. 52, doi. 10.1080/19466315.2016.1197150
- By:
- Publication type:
- Article
Considerations on Endpoint Selection, Weighting Determination, and Uncertainty Evaluation in the Benefit-Risk Assessment of Medical Product.
- Published in:
- Statistics in Biopharmaceutical Research, 2016, v. 8, n. 4, p. 417, doi. 10.1080/19466315.2016.1234974
- By:
- Publication type:
- Article
Practical Analysis and Visualization Tools for Benefit-Risk Assessment in Drug Development: A Review of Recent FDA Advisory Committee Meeting Packages.
- Published in:
- Statistics in Biopharmaceutical Research, 2016, v. 8, n. 4, p. 409, doi. 10.1080/19466315.2016.1231077
- By:
- Publication type:
- Article
Perspective: Multiplicity and Subgroups in the Context of Benefit–Risk Assessment.
- Published in:
- Statistics in Biopharmaceutical Research, 2016, v. 8, n. 4, p. 404, doi. 10.1080/19466315.2016.1226945
- By:
- Publication type:
- Article
Selecting and Integrating Data Sources in Benefit–Risk Assessment: Considerations and Future Directions.
- Published in:
- Statistics in Biopharmaceutical Research, 2016, v. 8, n. 4, p. 394, doi. 10.1080/19466315.2016.1225596
- By:
- Publication type:
- Article
Evaluation and Review of Strategies to Assess Cardiovascular Risk in Clinical Trials in Patients with Type 2 Diabetes Mellitus.
- Published in:
- Statistics in Biopharmaceutical Research, 2015, v. 7, n. 4, p. 253, doi. 10.1080/19466315.2015.1077724
- By:
- Publication type:
- Article
The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations.
- Published in:
- Statistics in Biopharmaceutical Research, 2015, v. 7, n. 3, p. 174, doi. 10.1080/19466315.2015.1043395
- By:
- Publication type:
- Article
A Revisit of Sample Size Decisions in Confirmatory Trials.
- Published in:
- Statistics in Biopharmaceutical Research, 2010, v. 2, n. 2, p. 239, doi. 10.1198/sbr.2009.0073
- By:
- Publication type:
- Article
Statisticians in the Pharmaceutical Industry: The 21st Century.
- Published in:
- Statistics in Biopharmaceutical Research, 2010, v. 2, n. 2, p. 145, doi. 10.1198/sbr.2009.0036
- By:
- Publication type:
- Article